RSV, Respiratory Syncytial Virus, is a common and highly contagious virus that affects the respiratory tracts of children under age 2 and is particularly dangerous for premature babies. RSV season can vary by location, but generally begins in the fall and runs through spring.
RSV is the most frequent reason for infant and young child hospitalizations during the winter months and can lead to bronchitis or pneumonia, which can be life-threatening or involve life-long complications. Predictions for this season have not yet been released, but according to the U.S. Centers for Disease Control and Prevention, RSV accounts for more than 57,000 hospitalizations of children under 5 each year. Another 2.1 million children under 5 receive outpatient care annually.
The most widespread prevention is Synagis, an injectable medication manufactured by Sobi. The series of injections are usually given at the pediatrician’s office at prices ranging from about $1,000 to more than $2,500 per shot.
TherigySTM offers an RSV patient care plan that enables specialty pharmacists who dispense Synagis to better track and manage the clinical care of their RSV patients.
Equally important, said Lily Duong, Therigy’s Chief Clinical Officer, the module is specifically developed to capture the data needed to meet Sobi’s reporting requirements.
“We are very pleased that the TherigySTM RSV patient care plan allows specialty pharmacies to provide superior clinical services for prevention of serious lung disease caused by RSV and also ease the concerns of worried parents,” she said. “This technical tool allows for enhanced tracking of care provided to Synagis patients and precise reporting of results back to Sobi.”
TherigySTM is the leading specialty therapy management tool used by specialty pharmacies across the United States. TherigySTM is best known for its patient care plans that give pharmacies of all sizes access to superior care for patients without the need for extensive on-staff clinical teams.
Synagis is available through specialty pharmacies and pharmacy networks in the United States and Canada, as well as directly to physicians and in numerous countries worldwide.
It is intended to be given before RSV season starts, to help protect children before the virus becomes active. During the fall and winter, children generally receive Synagis shots every 28-30 days to continue protection until the end of the season. Synagis is not a vaccine and does not prevent the infection, though it can lessen the severity of RSV in some premature infants.
To find out more about TherigySTM's RSV patient care plan, contact us today.